Abstract
Administration of a clade C/B' candidate HIV-1 DNA vaccine, ADVAX, by in vivo electroporation (EP) was safe and more immunogenic than intramuscular administration without EP. The breadth and specificity of T-cell responses to full-length Env were mapped. Responses to multiple Env regions were induced, with most focusing on V3/C4 and V2 regions, including the α4β7 integrin-binding domain. The breadth of responses induced by this DNA vaccine regimen was comparable to that of viral-vectored vaccine regimens.
Publication types
-
Clinical Trial
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
CD4-Positive T-Lymphocytes / immunology*
-
Electroporation / methods*
-
HIV Envelope Protein gp120 / genetics
-
HIV Envelope Protein gp120 / immunology*
-
HIV-1 / genetics
-
HIV-1 / immunology*
-
Healthy Volunteers
-
Humans
-
Inulin / administration & dosage
-
Inulin / adverse effects
-
Inulin / analogs & derivatives*
-
Inulin / immunology
-
Vaccination / methods
-
Vaccines, DNA / administration & dosage
-
Vaccines, DNA / adverse effects
-
Vaccines, DNA / immunology*
Substances
-
HIV Envelope Protein gp120
-
Vaccines, DNA
-
delta inulin
-
gp120 protein, Human immunodeficiency virus 1
-
Inulin